Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment

被引：15
|
作者：
Yang, Fei-Fei [1 ,2 ,3 ,4 ]
Hu, Ting [1 ,2 ,3 ,4 ]
Liu, Jian-Quan [1 ,2 ,3 ,4 ]
Yu, Xiao-Qian [1 ,2 ,3 ,4 ]
Ma, Li-Ying [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Minist Educ China, Key Lab Adv Pharmaceut Technol, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Inst Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[4] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[5] China Meheco Topfond Pharmaceut Co, Key Lab Cardio Cerebrovasc Drug, Zhumadian 463000, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 245卷
基金：
中国博士后科学基金;
关键词：
Hematologic cancer; HDACs; Immunotherapy; NKG2D LIGAND EXPRESSION; B-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; NON-HODGKIN-LYMPHOMA; REGULATORY T-CELLS; MULTIPLE-MYELOMA; ANTITUMOR IMMUNITY; VALPROIC ACID; TUMOR-CELLS; IN-VIVO;
D O I：
10.1016/j.ejmech.2022.114920
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Bone marrow transplantation is regarded as the most effective immunotherapy for hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of histone deacetylases (HDACs) is closely related to the occurrence and development of hematological cancer. Recent studies suggested that HDACs might play a critical role in initiating anti-cancer immune response or enhancing anti-cancer immunotherapy. Besides, combining HDAC inhibition and immunotherapy could prevent immunotherapy resistance in some degree and reach an extended treatment window. This review summarized the relationship between HDACs and immune and described the current understanding of HDACs in immunotherapy for hematologic cancer.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] HISTONE DEACETYLASES AS TARGETS FOR THE TREATMENT OF HUMAN NEURODEGENERATIVE DISEASES
    D'Mello, Santosh R.
    DRUG NEWS & PERSPECTIVES, 2009, 22 (09) : 513 - 524
  • [22] The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
    Bassett, Shalome A.
    Barnett, Matthew P. G.
    NUTRIENTS, 2014, 6 (10): : 4273 - 4301
  • [23] Changes in histone deacetylases (HDACs) in glaucomatous optic nerve.
    Guzman, Wendy
    Singh, Sudha
    Husain, Shahid
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [24] Deregulation of histone acetyltransferases (HATs) and deacetylases (HDACs) in urothelial carcinoma
    Koutsogiannouli, E.
    Pinkerneil, M.
    Niegisch, G.
    Hoffmann, M. J.
    Schulz, W. A.
    FEBS JOURNAL, 2015, 282 : 263 - 263
  • [25] Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis
    Li, Xing
    Wu, Xiao-Qin
    Xu, Tao
    Li, Xiao-Feng
    Yang, Yang
    Li, Wan-Xia
    Huang, Cheng
    Meng, Xiao-Ming
    Li, Jun
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2016, 306 : 58 - 68
  • [26] Histones and lung cancer: are the histone deacetylases a promising therapeutic target?
    Petta, Vasiliki
    Gkiozos, Ioannis
    Strimpakos, Alex
    Syrigos, Konstantinos
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 935 - 952
  • [27] Histones and lung cancer: are the histone deacetylases a promising therapeutic target?
    Vasiliki Petta
    Ioannis Gkiozos
    Alex Strimpakos
    Konstantinos Syrigos
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 935 - 952
  • [28] Chromatin meets cancer - Histone deacetylases as targets in cervical cancer therapy
    不详
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2005, 121 : 8 - 8
  • [29] Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
    Mottet, D.
    Castronovo, V.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 898 - 913
  • [30] Histone deacetylases function as novel potential therapeutic targets for cancer
    Zhang, Hui
    Shang, Yu-Ping
    Chen, Hong-ying
    Li, Jun
    HEPATOLOGY RESEARCH, 2017, 47 (02) : 149 - 159
12345